Literature DB >> 8878610

Once-daily aminoglycoside therapy: potential ototoxicity.

C Singer1, C Smith, D Krieff.   

Abstract

Current data indicate that once-daily aminoglycoside therapy is as efficacious as traditional multiple daily dosing and equally or less toxic. Our experience with once-daily gentamicin, 6 mg/kg of body weight led to a 10% (3 of 33 patients) occurrence of documented ototoxicity after prolonged aminoglycoside exposure.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8878610      PMCID： PMC163502     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

3.  Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection.

Authors:  P Van der Auwera; F Meunier; S Ibrahim; L Kaufman; M P Derde; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 4.  Aminoglycosides: another perspective.

Authors:  M W Garrison; D E Zaske; J C Rotschafer
Journal:  DICP       Date:  1990-03

5.  A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections.

Authors:  L F Hollender; J Bahnini; N De Manzini; W Y Lau; S T Fan; K Hermansyur; P Benny; A N Husni; R R Lorber
Journal:  J Antimicrob Chemother       Date:  1989-05       Impact factor: 5.790

6.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

7.  Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-01       Impact factor: 5.226

Review 8.  Once-daily administration of aminoglycosides.

Authors:  R D Bates; M C Nahata
Journal:  Ann Pharmacother       Date:  1994-06       Impact factor: 3.154

9.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Authors:  D P Nicolau; C D Freeman; P P Belliveau; C H Nightingale; J W Ross; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.

Authors:  R Ferriols-Lisart; M Alós-Almiñana
Journal:  Am J Health Syst Pharm       Date:  1996-05-15       Impact factor: 2.637
  10 in total
  3 in total

1.  Aminoglycoside dosage regimens after therapeutic drug monitoring.

Authors:  Carl M J Kirkpatrick; Evan J Begg; Murray L Barclay; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 3.  Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly.

Authors:  E Triggs; B Charles
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.